blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

Latvia joins the Federated Register
Click here for more information on the Federated Register.

2025-04-16

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2981272

EP2981272 - MICROPOROUS ZIRCONIUM SILICATE AND DIURETICS FOR THE REDUCTION OF POTASSIUM AND TREATMENT OF CHRONIC KIDNEY AND/OR CHRONIC HEART DISEASE [Right-click to bookmark this link]
StatusThe patent has been granted
Status updated on  27.01.2023
Database last updated on 26.04.2025
FormerGrant of patent is intended
Status updated on  12.12.2022
FormerExamination is in progress
Status updated on  24.10.2022
FormerGrant of patent is intended
Status updated on  01.08.2022
FormerExamination is in progress
Status updated on  24.07.2019
Most recent event   Tooltip27.03.2025New entry: Despatch of minutes of oral proceedings 
Applicant(s)For all designated states
ZS Pharma, Inc
508 Wrangler Dr., Suite 100
Coppell, TX 75019 / US
[2023/09]
Former [2016/06]For all designated states
ZS Pharma, Inc
508 Wrangler Dr., Suite 100
Coppell, TX 75019-7609 / US
Inventor(s)01 / KEYSER, Donald Jeffrey
1216 Wyndham Hill Lane
Southlake, Texas 76092 / US
02 / GUILLEM, Alvaro F.
727 Lathrop Street
Lantana, Texas 76226 / US
 [2016/06]
Representative(s)Carpmaels & Ransford LLP
One Southampton Row
London WC1B 5HA / GB
[N/P]
Former [2023/09]AstraZeneca Intellectual Property
Eastbrook House
Shaftesbury Road
Cambridge CB2 8BF / GB
Former [2016/06]D Young & Co LLP
120 Holborn
London EC1N 2DY / GB
Application number, filing date14779186.703.04.2014
[2016/06]
WO2014US32815
Priority number, dateUS201361808897P05.04.2013         Original published format: US 201361808897 P
US201361914362P10.12.2013         Original published format: US 201361914362 P
US201461930331P22.01.2014         Original published format: US 201461930331 P
[2016/06]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2014165670
Date:09.10.2014
Language:EN
[2014/41]
Type: A1 Application with search report 
No.:EP2981272
Date:10.02.2016
Language:EN
The application published by WIPO in one of the EPO official languages on 09.10.2014 takes the place of the publication of the European patent application.
[2016/06]
Type: B1 Patent specification 
No.:EP2981272
Date:01.03.2023
Language:EN
[2023/09]
Search report(s)International search report - published on:US09.10.2014
(Supplementary) European search report - dispatched on:EP09.11.2016
ClassificationIPC:A61K31/585, A61K31/495, A61K31/519, A61P5/40, A61P13/12, A61P9/00, A61P3/12, A61K33/24
[2022/32]
CPC:
A61K33/24 (EP,IL,US); A61K31/4184 (EP,IL,US); A61K38/06 (EP,IL,US);
A61K45/06 (EP,IL,US); A61K9/16 (IL,US); A61P13/12 (EP,IL);
A61P3/12 (EP,IL); A61P43/00 (EP,IL); A61P5/40 (EP,IL);
A61P7/12 (EP,IL); A61P9/00 (EP,IL); A61P9/04 (EP,IL);
C01B39/00 (EP,IL,US); Y02A50/30 (EP,US) (-)
C-Set:
A61K33/24, A61K2300/00 (EP,US)
Former IPC [2016/49]A61K33/24, A61P3/12, A61P5/40, A61P13/12, A61P9/00
Former IPC [2016/06]A61K33/24
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2016/06]
Extension statesBANot yet paid
MENot yet paid
TitleGerman:MIKROPORÖSES ZIRKONIUMSILIKAT UND DIURETIKA ZUR REDUKTION VON KALIUM UND BEHANDLUNG CHRONISCHER NIEREN- UND/ODER CHRONISCHER HERZERKRANKUNGEN[2016/06]
English:MICROPOROUS ZIRCONIUM SILICATE AND DIURETICS FOR THE REDUCTION OF POTASSIUM AND TREATMENT OF CHRONIC KIDNEY AND/OR CHRONIC HEART DISEASE[2016/06]
French:SILICATE DE ZIRCONIUM MICROPOREUX ET AGENTS DIURÉTIQUES POUR LA RÉDUCTION DU POTASSIUM ET LE TRAITEMENT D'UNE MALADIE RÉNALE CHRONIQUE ET/OU CARDIAQUE CHRONIQUE[2016/06]
Entry into regional phase05.11.2015National basic fee paid 
05.11.2015Search fee paid 
05.11.2015Designation fee(s) paid 
05.11.2015Examination fee paid 
Examination procedure05.11.2015Examination requested  [2016/06]
26.05.2017Amendment by applicant (claims and/or description)
29.07.2019Despatch of a communication from the examining division (Time limit: M04)
27.11.2019Reply to a communication from the examining division
21.10.2020Despatch of a communication from the examining division (Time limit: M04)
19.02.2021Reply to a communication from the examining division
02.08.2022Communication of intention to grant the patent
21.10.2022Disapproval of the communication of intention to grant the patent by the applicant or resumption of examination proceedings by the EPO
13.12.2022Communication of intention to grant the patent
19.01.2023Fee for grant paid
19.01.2023Fee for publishing/printing paid
19.01.2023Receipt of the translation of the claim(s)
Opposition(s)Opponent(s)01  22.11.2023  23.11.2023  ADMISSIBLE
Teva Pharmaceutical Industries Ltd.
124 Dvora HaNevi'a St.
Tel Aviv 6944020 / IL
Opponent's representative
Kraus & Lederer PartGmbB
Thomas-Wimmer-Ring 15
80539 München / DE
 02  01.12.2023  04.12.2023  ADMISSIBLE
Generics (U.K.) Limited
Building 4, Trident Place
Mosquito Way
Hatfield
Hertfordshire AL10 9UL / GB
Opponent's representative
Elkington and Fife LLP
Prospect House
8 Pembroke Road
Sevenoaks, Kent TN13 1XR / GB
 [N/P]
Former [2024/04]
Opponent(s)01  22.11.2023  23.11.2023  ADMISSIBLE
Teva Pharmaceutical Industries Ltd.
124 Dvora HaNevi'a St.
Tel Aviv 6944020 / IL
Opponent's representative
Kraus & Weisert Patentanwälte PartGmbB
Thomas-Wimmer-Ring 15
80539 München / DE
 02  01.12.2023  04.12.2023  ADMISSIBLE
Generics (U.K.) Limited
Building 4, Trident Place
Mosquito Way
Hatfield
Hertfordshire AL10 9UL / GB
Opponent's representative
Elkington and Fife LLP
Prospect House
8 Pembroke Road
Sevenoaks, Kent TN13 1XR / GB
Former [2024/02]
Opponent(s)01  22.11.2023  23.11.2023  ADMISSIBLE
Teva Pharmaceutical Industries Ltd.
124 Dvora HaNevi'a St.
Tel Aviv 6944020 / IL
Opponent's representative
Lederer & Keller Patentanwälte Partnerschaft mbB
Unsöldstraße 2
80538 München / DE
 02  01.12.2023  04.12.2023  ADMISSIBLE
Generics (U.K.) Limited
Building 4, Trident Place
Mosquito Way
Hatfield
Hertfordshire AL10 9UL / GB
Opponent's representative
Elkington and Fife LLP
Prospect House
8 Pembroke Road
Sevenoaks, Kent TN13 1XR / GB
Former [2023/52]
Opponent(s)01  22.11.2023  23.11.2023  ADMISSIBLE
Teva Pharmaceutical Industries Ltd.
124 Dvora HaNevi'a St.
Tel Aviv 6944020 / IL
Opponent's representative
Lederer & Keller Patentanwälte Partnerschaft mbB
Unsöldstraße 2
80538 München / DE
13.12.2023Invitation to proprietor to file observations on the notice of opposition
12.04.2024Reply of patent proprietor to notice(s) of opposition
06.03.2025Date of oral proceedings
26.03.2025Despatch of minutes of oral proceedings
26.03.2025Despatch of communication that the patent will be revoked
Fees paidRenewal fee
28.04.2016Renewal fee patent year 03
19.04.2017Renewal fee patent year 04
11.04.2018Renewal fee patent year 05
15.04.2019Renewal fee patent year 06
30.04.2020Renewal fee patent year 07
30.04.2021Renewal fee patent year 08
02.05.2022Renewal fee patent year 09
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipBG01.03.2023
EE01.03.2023
HR01.03.2023
LT01.03.2023
LV01.03.2023
MC01.03.2023
RS01.03.2023
SI01.03.2023
SK01.03.2023
SM01.03.2023
LU03.04.2023
IS01.07.2023
[2024/51]
Former [2024/11]EE01.03.2023
HR01.03.2023
LT01.03.2023
LV01.03.2023
MC01.03.2023
RS01.03.2023
SI01.03.2023
SK01.03.2023
SM01.03.2023
LU03.04.2023
IS01.07.2023
Former [2024/08]EE01.03.2023
HR01.03.2023
LT01.03.2023
LV01.03.2023
MC01.03.2023
RS01.03.2023
SK01.03.2023
SM01.03.2023
LU03.04.2023
IS01.07.2023
Former [2024/04]EE01.03.2023
HR01.03.2023
LT01.03.2023
LV01.03.2023
RS01.03.2023
SK01.03.2023
SM01.03.2023
LU03.04.2023
IS01.07.2023
Former [2023/50]EE01.03.2023
HR01.03.2023
LT01.03.2023
LV01.03.2023
RS01.03.2023
SK01.03.2023
SM01.03.2023
IS01.07.2023
Former [2023/48]EE01.03.2023
HR01.03.2023
LT01.03.2023
LV01.03.2023
RS01.03.2023
SM01.03.2023
Former [2023/46]HR01.03.2023
LT01.03.2023
LV01.03.2023
RS01.03.2023
SM01.03.2023
Former [2023/36]HR01.03.2023
LT01.03.2023
LV01.03.2023
RS01.03.2023
Former [2023/35]HR01.03.2023
LT01.03.2023
RS01.03.2023
Former [2023/34]LT01.03.2023
RS01.03.2023
Former [2023/33]LT01.03.2023
Documents cited:Search[X]WO02062356  (ASH MEDICAL SYSTEMS INC [US], et al);
 [A]US6579460  (WILLIS RICHARD R [US], et al);
 [A]WO2012109590  (ZS PHARMA INC [US], et al);
 [PX]WO2014011876  (ZS PHARMA INC [US], et al);
 [E]WO2014066407  (ZS PHARMA INC [US])
International search[Y]US5891417  (BEM DAVID S [US], et al);
 [Y]US6159505  (PIPER EDWINA M [GB]);
 [Y]US2004105895  (ASH STEPHEN R [US]);
 [Y]US2010104527  (MANSKY PAUL [US], et al);
 [X]US2012213847  (KEYSER DONALD JEFFREY [US], et al)
ExaminationUS2014113002
OppositionUS6332985
 WO02062356
 WO2012109590
 WO2014011876
 US5891417
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.